The neutropenia observed in G6PC3 or G6PT deficiency is therefore caused by a defect of metabolite repair (see Figure 1B), which might be responsive to treatment with inhibitors of the Na+‐dependent glucose transporter of the kidney (SGLT2), currently used in the treatment of type II diabetes. This evidence concerns the gene G6PC1 and Decreased total neutrophil count.